These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 26638442)

  • 1. [INITIATING AND INTENSIFYING INSULIN THERAPY IN GENERAL PRACTICE: INSUSTAR, AN OBSERVATIONAL BELGIAN PROSPECTIVE STUDY IN TYPE 2 DIABETES].
    Scheen AJ; Mathieu C; Nobels F
    Rev Med Liege; 2015 Sep; 70(9):423-31. PubMed ID: 26638442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
    Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
    Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
    Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
    Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
    Mathur SK; Bansal A; Khan ZY
    J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 diabetes mellitus--guidelines for initiating insulin therapy.
    Yeap BB
    Aust Fam Physician; 2007 Jul; 36(7):549-53. PubMed ID: 17619673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel and Emerging Insulin Preparations for Type 2 Diabetes.
    Cheung KK; Alexander P
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S160-6. PubMed ID: 26653255
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G; Laurenti O; Moretti A
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
    Khunti K; Cos X; Rutten G
    Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions.
    Lefever E; Vliebergh J; Mathieu C
    Expert Opin Drug Saf; 2021 Feb; 20(2):155-169. PubMed ID: 33249944
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycaemic control by monoamine oxidase inhibition in a patient with type 1 diabetes.
    Emory H; Mizrahi N
    Diab Vasc Dis Res; 2017 Mar; 14(2):163-165. PubMed ID: 27884951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded table: some available insulins for type 2 diabetes.
    Med Lett Drugs Ther; 2019 May; 61(1571):e73-e77. PubMed ID: 31169807
    [No Abstract]   [Full Text] [Related]  

  • 17. Concentrated insulins: History and critical reappraisal.
    Heinemann L; Beals JM; Malone J; Anderson J; Jacobson JG; Sinha V; Corrigan SM
    J Diabetes; 2019 Apr; 11(4):292-300. PubMed ID: 30264527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycaemia causes both daytime and nighttime QTc interval prolongation in patients with type 2 diabetes receiving insulin treatment.
    Makrilakis K; Stathi C; Vlahodimitris I; Kalopita S; Thomakos P; Konstantopoulos P; Perrea D; Katsilambros N; Liatis S
    Diabetes Metab; 2018 Mar; 44(2):175-177. PubMed ID: 29029946
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacologic treatment options for type 1 diabetes: what's new?
    Nally LM; Sherr JL; Van Name MA; Patel AD; Tamborlane WV
    Expert Rev Clin Pharmacol; 2019 May; 12(5):471-479. PubMed ID: 30892094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [News in diabetology 2015].
    Jornayvaz FR
    Rev Med Suisse; 2016 Jan; 12(500):30-1. PubMed ID: 26946699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.